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Prolonged enoxaparin therapy compared with standard-of-care 
antithrombotic therapy in opiate-treated patients undergoing primary 
percutaneous coronary intervention
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Abstract
A novel enoxaparin regimen consisting of intra-arterial bolus (0.75 mg/kg) followed by intrave-
nous infusion (0.75 mg/kg/6 hours) has been developed as a possible solution to the delayed 
absorption of oral P2Y12 inhibitors in opiate-treated ST-elevation myocardial infarction (STEMI) 
patients undergoing primary angioplasty. We aimed to study the feasibility of this regimen as an 
alternative to standard-of-care treatment (SOC) with unfractionated heparin ± glycoprotein IIb/IIIa 
antagonist (GPI). One hundred opiate-treated patients presenting with STEMI and accepted for 
primary angioplasty were randomized (1:1) to either enoxaparin or SOC. Fifty patients were 
allocated enoxaparin (median age 61, 40% females) and 49 allocated SOC (median age 62, 22% 
females). One developed stroke before angiography and was withdrawn. One SOC patient had 
a gastrointestinal bleed resulting in 1 g drop in hemoglobin and early cessation of GPI infusion. 
Two enoxaparin patients had transient minor bleeding: one transient gingival bleed and one 
episode of coffee ground vomit with no hemoglobin drop or hemodynamic instability. Two SOC 
and no enoxaparin group patients had acute stent thrombosis. These preliminary data support 
further study of this novel 6-hour enoxaparin regimen in opiate-treated PPCI patients.
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Introduction
Dual antiplatelet therapy is essential to safely perform percutaneous 
coronary intervention (PCI) [1]. Potent P2Y12 inhibitors (ticagrelor/ 
prasugrel) are preferred to clopidogrel in acute coronary syndrome 
(ACS) patients [1–3] in view of their more rapid and consistent 
antiplatelet effect [4–6]. However, in opiate-treated patients under-
going primary PCI (PPCI) for ST-elevation myocardial infarction 
(STEMI), absorption and, therefore, onset of action can be delayed 
by up to 6–8 hours [7–9]. This can increase the risk of acute thrombotic 
complications and so strategies to deal with this issue are needed 
[10,11]. The negative interaction between opiates and oral P2Y12 
inhibitors was also noted in patients with non-ST-elevation ACS 
undergoing early catheterization and this may have resulted in 
increased thrombotic risk [12]. Available solutions have been limited 
by added cost and increased risk of bleeding [13,14]. For example, we 
have recently demonstrated a reduction in acute stent thrombosis with 
an institutional protocol employing routine use of a 6-hour regimen of 
tirofiban in opiate-treated patients undergoing PPCI but at the expense 
of more bleeding [10,11]. Enoxaparin, in conjunction with antithrom-
bin, directly inhibits thrombin-induced platelet activation and also 
inhibits thrombin generation through inhibition of factor Xa, thus 
indirectly reducing thrombin-induced platelet activation in vivo [15]. 
A novel regimen consisting of a bolus intra-arterial (IA) enoxaparin 
(0.75 mg/kg) followed by an intravenous (IV) enoxaparin infusion 
(0.75 mg/kg/6 hours) has been shown to result in sustained antithrom-
botic effects 6 hours post-PPCI [15]. We hypothesize that this enox-
aparin-based regimen is sufficient to circumvent the risk associated 
with delayed absorption of oral antiplatelet therapy. A bolus dose of 
enoxaparin (0.5 to 0.75 mg/kg) is acceptable as an alternative to a bolus 
of unfractionated heparin (UFH) in patients undergoing PPCI [3,16]. 
Similarly, the safety and efficacy of subcutaneous enoxaparin (1 mg/kg 
twice daily) are well established in patients with non-ST-elevation 
ACS [17]. An infusion of enoxaparin following the bolus dose in the 
context of PPCI is more desirable than a subcutaneous approach, given 
the more rapid onset of action and avoidance of excessive peak anti-Xa 
levels [18]. In this study, we aimed to assess the feasibility of using this 
enoxaparin regimen (IV/IA bolus enoxaparin 0.75 mg/kg + IV infu-
sion 0.75 mg/kg/6 hours) as an alternative to the local SOC, which 
consists of IV/IA UFH bolus ± the glycoprotein IIb/IIIa inhibitor 
(GPI) tirofiban in opiate-treated patients undergoing PPCI.
Materials and Methods
Study Design and Ethical Considerations
This was a single-center, open-label, feasibility, randomized con-
trolled trial. All study patients provided informed consent accord-
ing to a protocol approved by the local research ethics committee 
(18/YH/0108) and the Medicines and Healthcare Products 
Regulatory Agency (MHRA), UK. The trial was registered at 
http://clinicaltrials.gov (unique identifier NCT03568838).
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Study Population, Randomization, and Intervention
Patients presenting with STEMI, pre-treated with opiates and 
accepted for PPCI were recruited if they met the inclusion and 
exclusion criteria as detailed in the supplement. Patients were 
randomized, after witnessed informed verbal consent, to either 
SOC or enoxaparin. Randomization was undertaken using sealed 
envelopes. Envelopes were opaque, tamper-proof, and prepared 
independently using random numbers from the Documenta Geigy 
scientific tables. Treatment was administered after insertion of the 
IA (intra-arterial) sheath if the diagnosis was confirmed. Patients 
allocated enoxaparin received IA bolus of enoxaparin (0.75 mg/ 
kg) followed by an IV enoxaparin infusion (0.75 mg/kg/6 h), as 
previously described [15]. We planned to stop the infusion at 
3 hours in patients with significant renal impairment 
(eGFR<30 ml/min/1.73 m2). GPI use was prohibited unless for 
bailout (no-reflow).
Patients allocated SOC received treatment at the discretion 
of the treating cardiologist. This consisted of weight-adjusted 
bolus dose of UFH 50–70 IU/kg + a 6-hour regimen of 
tirofiban (or UFH 70 IU/kg alone if concerns about bleeding 
risk). This regimen of tirofiban consisted of tirofiban 25 mcg/ 
kg over 3 minutes (or 6 minutes if weight > 120 kg) followed 
by maintenance dose of 0.15 mcg/kg/min for patients with 
eGFR ≥30 ml/min/1.73 m2 for 6 hours and half these doses 
if eGFR<30 ml/min/1.73 m2.
As soon as possible following PPCI, written informed consent 
was obtained. If a patient died before obtaining written consent, 
data obtained under verbal consent were retained, as approved by 
the research ethics committee.
Patients were followed up at 24 hours and 30 days. The 
primary feasibility outcome was recruitment rate. The primary 
clinical outcome was bleeding events of at least type 2 severity as 
classified by the Bleeding Academic Research Consortium 
(BARC) [19]. Secondary endpoints included death, definite or 
probable stent thrombosis as defined by the Academic Research 
Consortium [20], and ST-segment resolution post-PPCI. Clinical 
events were adjudicated by two investigators independently (WS 
and RFS). ST-segment resolution was calculated within 1 hour of 
PPCI by an investigator (WAEP) blinded to treatment allocation, 
using standard criteria [21,22].
Statistical Analysis
Continuous data are presented as median (quartile 1, quartile 3) 
and compared using the Mann–Whitney test. Categorical data are 
presented as number (%) and compared using the Chi-square test. 
Results with P-values < 0.05 were considered statistically signif-
icant. Statistical analyses were performed using GraphPad Prism 
7 for Mac OS X. This was a feasibility study and clinical data are 
only reported as pilot data since the study was not powered for 
clinical outcomes.
Results
Baseline, Procedural Characteristics, and Feasibility 
Outcomes
One hundred and eighty-nine patients were screened between end 
of June 2018 and beginning of March 2019. Thirty-three patients 
did not meet the eligibility criteria, two declined to participate, 
and the dedicated research team were not available to obtain 
verbal consent in 54 patients. Patients meeting eligibility criteria 
and able to provide consent (n = 100) were recruited: 50 in the 
enoxaparin group, 49 in the SOC group, and one was withdrawn 
as he developed stroke after verbal consent but before coronary 
angiography or receiving any treatment (Figure 1). All patients 
had received morphine and/or diamorphine (Table I). Baseline 
demographics, risk factors, and procedural characteristics were 
well matched between the two treatment groups (Table I). There 
were slightly more females in the enoxaparin group compared to 
the SOC group (P = .06). All patients received oral aspirin and 
either ticagrelor (98 patients) or prasugrel (1 patient). Radial 
artery access was used in the majority of patients (Table I). 
Three enoxaparin patients were switched to tirofiban for bailout 
(poor or no re-flow). Forty of the 49 SOC patients received 
tirofiban, three of whom had poor or no re-flow.
Clinical Outcomes and ST-segment Resolution
Bleeding events: One out of 49 SOC patients had a type 2 BARC 
bleeding event. The patient vomited fresh blood resulting in 1 g/ 
dL fall in hemoglobin. The tirofiban infusion was stopped.
Figure 1. Study flowchart STEMI: ST-elevation 
myocardial infarction; PPCI: primary percuta-
neous coronary intervention; UFH: unfractio-
nated heparin.
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Two out of 50 enoxaparin patients had type 1 BARC bleeding 
events. One had a transient gingival bleed and another had an 
episode of coffee ground vomit. These did not result in a fall in 
hemoglobin, hemodynamic instability, or change of treatment.
Acute stent thrombosis: Two out of 49 SOC patients developed 
acute stent thrombosis. One had successful PPCI to the right 
coronary artery (RCA) and was treated with UFH without GPI; 
approximately 40 minutes after UFH, the patient developed recur-
rent chest pain and ST-elevation, diagnosed as acute stent throm-
bosis, and died following decision to manage this conservatively 
due to age and co-morbidities that had not been appreciated at the 
time of emergency angiography. The other patient had PPCI to an 
ectatic RCA but had TIMI-2 flow with high thrombus burden that 
was treated with UFH and a 48-hour tirofiban infusion. About 
8 hours following PPCI, this patient developed further chest pain 
with recurrent ST-elevation, and repeat angiography confirmed 
stent thrombosis. However, this was not treated as, by the time 
repeat angiography was performed, the patient was pain-free and 
had already developed collateral supply. No patient in the enox-
aparin group suffered an acute thrombotic event.
30-day outcomes: Except for the 2 SOC patients with acute 
stent thrombosis who had evidence of recurrent STEMI, no 
patients suffered recurrent ACS within 30 days and no patient 
suffered a stroke. In the SOC group, there were no further deaths 
in addition to the one patient who died as a result of acute stent 
thrombosis. In the enoxaparin group, one patient was re-admitted 
with heart failure approximately 2 weeks after discharge and 
subsequently died from left ventricular failure.
Clinical outcomes are summarized in Figure 1.
There was no significant difference in % of ST segment reso-
lution between enoxaparin and SOC groups (P = .44) (Figure 2).
Discussion
In previous work, we demonstrated that an enoxaparin regimen 
consisting of 0.75 mg/kg bolus followed by intravenous infusion 
of 0.75 mg/kg over 6 hours resulted in sustained antithrombotic 
effects throughout the infusion, up to 6 hours post PPCI [15]. This 
is the first randomized feasibility trial to suggest feasibility of this 
novel regimen in opiate-treated STEMI patients undergoing PPCI, 
in comparison with standard parenteral antithrombotic therapy, 
and provides reassuring pilot data to support future trials.
Bolus enoxaparin (0.5–0.75 mg/kg) is approved as an alter-
native to bolus UFH to support the PPCI procedure [3,16]. IV 
enoxaparin half-life is 1–2 hours [23]. The novel approach to 
follow the bolus dose with an infusion has been designed to 
bridge the gap in antithrombotic therapy shortly after PPCI. 
This may represent an inexpensive solution to the delayed anti-
platelet effect of oral therapy. As an anticoagulant, enoxaparin 
inhibits thrombin generation and, in conjunction with plasma 
antithrombin, thrombin-induced platelet activation [15].
It should be emphasized that clinical outcomes described here 
are only hypothesis-generating, as our study lacks sufficient 
power to demonstrate efficacy or safety. Furthermore, the rate 
of stent thrombosis in the SOC patients (4%) was higher than 
expected and likely due to chance since we have recently shown 
that introduction of our institutional guideline for the use of 
a 6-hour tirofiban regimen in opiate-treated patients undergoing 
PPCI was associated with a reduction in 30-day stent thrombosis 
rates to 0.6% [11]. These results, however, highlight the potential 
caveats with current SOC. Although the risk of stent thrombosis is 
small, consequences, as was the case in one of our patients, can be 
catastrophic. Furthermore, one patient developed stent thrombosis 
despite treatment with GPI, indicating that GPI may not be 
successful at preventing stent thrombosis in poor flow conditions. 
We also observed one patient developed fresh hematemesis while 
receiving GPI. This highlights the potential risk of using routine 
GPI in combination with heparin and dual oral antiplatelet ther-
apy in view of the expected severe effect on hemostasis of this 
combination.
The open-label design of the study is another limitation. 
However, due to the nature of the study recruiting STEMI 
patients, it was logistically challenging to blind investigators/ 
patients from treatment allocation and no pharmaceutical com-
pany support was available to support a double-blind approach.
The lack of difference in ST resolution between the two 
strategies suggests a lack of differential effect on impairment of 
the microvascular circulation. Other work has shown that potent 
P2Y12 inhibition at the time of PPCI with cangrelor did not 
translate into improvement in infarct size or microvascular circu-
lation [24]. As such, it appears that antithrombotic treatment is 
needed as a preventative therapy rather than as an intervention to 
aid microvascular circulation. Although cangrelor may be an 
attractive option to circumvent the delayed absorption of ticagre-
lor or prasugrel, it has only been studied as a 2–4 hour infusion, 
which may not be sufficient to cover the delayed onset of action 
of oral P2Y12 inhibitors in all patients [14,24]. Furthermore, it 
may not be affordable in many healthcare settings to offer can-
grelor as a routine 6-hour infusion to opiate-treated STEMI 
Table I. Baseline and procedural characteristics.
Enoxaparin 
(n = 50)
Standard-of-Care 
(n = 49) P value
Demographics
Age (yrs) 61 (55–73) 62 (35–71) 0.52
Female sex 20 (40%) 11 (22%) 0.06
BMI (kg/m2) 28 (25–30) 28 (26–30) 0.54
Race 0.22
White 49 (98%) 47 (96%)
Black 1 (2%) 0 (0%)
Asian 0 (0%) 2 (4%)
Background history
Current or past smoker 33 (66%) 36 (73.5%) 0.42
Hypertension 25 (50%) 21 (43%) 0.48
Dyslipidaemia 20 (40%) 19 (39%) 0.9
Diabetes mellitus 12 (24%) 10 (20%) 0.67
Previous MI 8 (16%) 5 (10%) 0.39
Previous PCI 7 (14%) 3 (6%) 0.19
Previous CABG 0 (0%) 1 (2%) 0.31
Cardiac failure 1 (2%) 1 (2%) 0.98
Cerebrovascular disease 2 (4%) 1 (2%) 0.57
Peripheral arterial disease 1 (2%) 0 (0%) 0.32
Procedural characteristics
Anterior territory 22 (45%) 17 (35%) 0.3
Radial access 44 (88%) 44 (90%) 0.78
Ticagrelor 180 mg 50 (100%) 48 (98%) 0.3
Prasugrel 60 mg 0 (0%) 1 (2%)
GPI use (tirofiban) 3 (6%) 40 (82%) <0.0001
Slow or no re-flow 3 (6%) 3 (6%) 0.97
Morphine (mg) 6.5 (4.75–10) 7.5 (5–10) 0.41
Diamorphine (mg) 5 (5–7.5) 3.75 (2.5–5) 0.08
Antiemetic treatment 42 (84%) 40 (82%) 0.75
Pain to balloon (mins) 176 (148–250) 210 (157–330) 0.23
Call to balloon (mins) 128 (110–161) 126 (105–182) 0.75
Door to balloon (mins) 44 (32–58) 42 (30–57) 0.72
Number of stents 1 (1–2) 1 (1–2) 0.87
Stent diameter (mm) 3 (3–3.5) 3.5 (3–4) 0.16
Stent length (mm) 23 (15–26) 23 (18–30) 0.17
Data presented as median (interquartile range) for continuous variables 
and number (%) for categorical variables. BMI: body mass index; MI: 
myocardial infarction; PCI: percutaneous coronary intervention; 
CABG: coronary artery bypass graft surgery; GPI: glycoprotein IIb/ 
IIIa inhibitor. P values were calculated using Chi-square or Mann– 
Whitney test as appropriate. 
DOI: https://doi.org/10.1080/09537104.2020.1779925                                                                                                                                  3 
patients undergoing PPCI. Selatogrel is a subcutaneous P2Y12 
inhibitor with rapid onset of action that is in phase II development 
and may provide an alternative treatment in the future [25].
Strategies to expedite absorption of oral therapy have been 
explored. These include using higher loading doses, chewing 
tablets, or using prokinetic antiemetic drugs [26–29]. However, 
these have only resulted in marginal acceleration of absorption, 
suggesting that parenteral treatment is still needed to cover the 
critical period following PPCI.
Conclusions
An IA bolus of enoxaparin (0.75 mg/kg) followed by IV enox-
aparin infusion (0.75 mg/kg/6 hours), in STEMI patients under-
going PPCI, appears to be suitable for further study to assess its 
efficacy and safety.
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